These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients. Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824 [TBL] [Abstract][Full Text] [Related]
10. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R Cells; 2019 Dec; 9(1):. PubMed ID: 31877771 [TBL] [Abstract][Full Text] [Related]
11. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580 [TBL] [Abstract][Full Text] [Related]
12. Roles of PPARs in NAFLD: potential therapeutic targets. Tailleux A; Wouters K; Staels B Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763 [TBL] [Abstract][Full Text] [Related]
13. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W Cells; 2020 Jul; 9(7):. PubMed ID: 32650421 [TBL] [Abstract][Full Text] [Related]
14. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255 [TBL] [Abstract][Full Text] [Related]
15. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. Kallwitz ER; McLachlan A; Cotler SJ World J Gastroenterol; 2008 Jan; 14(1):22-8. PubMed ID: 18176957 [TBL] [Abstract][Full Text] [Related]
16. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Kamata S; Honda A; Ishii I Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627329 [TBL] [Abstract][Full Text] [Related]
17. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367 [TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. Souza-Mello V World J Hepatol; 2015 May; 7(8):1012-9. PubMed ID: 26052390 [TBL] [Abstract][Full Text] [Related]
19. The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. Li YY; Cao CY; Zhou YL; Nie YQ; Cao J; Zhou YJ Arab J Gastroenterol; 2020 Sep; 21(3):162-168. PubMed ID: 32451200 [TBL] [Abstract][Full Text] [Related]
20. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]